Navigation Links
Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd.
Date:5/13/2008

BEIJING and CLAREMONT, Calif., May 13 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) announced finalization of an agreement establishing a joint venture company capable of producing Kiwa's AF-01 anti-viral product.

On May 9, General Manager of Shijiazhuang Huaxing Animal Medicine Co., Ltd. (''Huaxing''), Mr. Ruijun Li and his associates visited Kiwa's headquarters in Beijing for the final round of negotiations toward setting up a proposed joint-venture. Both parties had extensively negotiated on the terms of the joint-venture contract and finally confirmed all terms of the contract.

The signing ceremony will be held next week, after the company name is approved by the local Administration of Industry and Commerce.

ABOUT AF-01 ANTI-VIRAL FEED ENHANCEMENT AND AEROSOL

In May 2006, Kiwa acquired AF-01 Anti-viral Aerosol technology for veterinary medicine applications including the exclusive production right and other related rights to produce an anti-viral aerosol drug for use with animals from Jinan Kelongboao Bio-Tech Co., Ltd. ("JKB"), which is affiliated with Chinese Academy of Medical Sciences. The AF-01 aerosol technology is a broad-spectrum anti-viral agent with potent inhibitory and/or viricidal effects on a variety of RNA viruses found in animals and fowls such as bird flu. Kiwa's hope is to develop a commercialized product in the form of a spray for applying in fowl houses and other animal holding facilities to prevent and cure virus-caused diseases.

ABOUT SHIJIAZHUANG HUAXING ANIMAL MEDICINE CO., LTD.

Huaxing was founded in 1996. Huaxing is supported by animal husbandry and veterinary medicine agencies at both provincial and municipal levels. Huaxing has focused on building strong co-operative relationships with academic institutions such as the Agricultural University of Heibei and Hebei University of Science & Technology. Huaxing has developed: 12-series o
'/>"/>

SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kiwa Bio-Tech 1st Quarter Revenues Increase 57.8% - $2.18 Million
2. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
3. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
4. Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada
5. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
6. Kiwa Bio-Tech Ships 114 Tons of Bio-Fertilizer in Fourth Quarter of 2007
7. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
8. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
9. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
10. Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million
11. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Longer-term Phase 2 Switching Study, CRANBURY, ... company developing small-molecule, orally administered,pharmacological chaperones for ... that the Company will present positive results ... (isofagomine tartrate) for Gaucher disease,at the American ...
... on the strangeness of the nanoworld, researchers at the ... University of Maryland-College Park have discovered that materials such ... behave as ductile as gold at the nanoscale. Their ... NIST scientists Pradeep Namboodiri and Doo-In Kim and colleagues ...
... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
Cached Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Nanomaterials show unexpected strength under stress 2
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... anachronism? Or is it a vital part of a ... 2.4 billion more people by the year 2050, the drive ... , But there,s an important downside to this trend, argues ... Montreal, in a paper to be presented Saturday, Feb. 15, ...
... Calif.) When mothers feed their newborns formula in the ... in the second month of life and more likely to ... longer, UC Davis researchers have found. "We are ... hospital can cause problems by reducing how much women breastfeed ...
... Rochelle, NY, February 13, 2014Food spoiling and poisoning caused ... economic problems. The broad scope of antimicrobial approaches to ... and beverages, including a variety of natural and artificial ... in Industrial Biotechnology , a peer-reviewed journal from ...
Cached Biology News:Making biodiverse agriculture part of a food-secure future 2Making biodiverse agriculture part of a food-secure future 3In-hospital formula use deters breastfeeding 2In-hospital formula use deters breastfeeding 3
... Ambion's ActivePro In ... from an E.coli lysate, ... protein as well as ... activity than competing kits. ...
... Mouse Serum • Mouse serum is collected off ... and 8-12 weeks of age. Available Anticoagulants: ... N-06: K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD ...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: